Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RN7SL182P is a **pseudogene** that derives from the human 7SL RNA gene, a component of the signal recognition particle (SRP) ribonucleoprotein complex involved in directing the trafficking of proteins within cells[1][4][8]. Pseudogenes are copies of functional genes that have lost their protein-coding ability or are otherwise nonfunctional, though some can be transcribed into RNA[5][8]. The RN7SL182P pseudogene itself does not encode any known functional protein or RNA, is not a receptor, enzyme, or conventional therapeutic target, and has no direct evidence of involvement in human disease or as a drug target[1][8]. Most 7SL RNA pseudogenes, including RN7SL182P, are considered genomic relics resulting from the reverse transcription and integration of RNA sequences back into DNA[8]. While some pseudogenes can act as regulators (e.g., as decoys for microRNAs or sources for small RNAs that might regulate gene expression), there is no specific evidence for such activity for RN7SL182P itself[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, 7SL, cytoplasmic 182, pseudogene (RN7SL182P).